Tweets
Full read review of the benefits & impact of hydroxychloroquine in #SLE. Benefits on:
- T cells, cytokines, TLR signaling
- VTE prevention
- Decr CV risks
- Glucose & lipid benefits
- Pregnancy
https://t.co/z9cooQwZux https://t.co/QumKoHgQDY
Dr. John Cush @RheumNow ( View Tweet )
1 year 8 months ago
FAERS retrospective, safety study of JAKi use in 75K RA pts (52K Tofa; 21K Upa, 2.2K Bari vs bDMARDs) found JAKi had incr risk of VTE (adj ROR=2.11), CVA (ROR=1.25), IHD (1.23), edema(1.22), & tachyarrhythmias (1.15) https://t.co/Bvds4C66Nq https://t.co/Xmu8g35MXR
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 year 8 months ago
Brazilian Registry of Spondyloarthritis study of 1096 SpA pts, found 73% HLA-B27 positivity. B27+ signif assoc w/ males, earlier onset/Dx, uveitis, +FHx. B27 negativity assoc w/ psoriasis, higher peripheral arthritis/disease activity, worse QOL, mobility https://t.co/ousSetEnrt https://t.co/ezSgHro8sQ
Dr. John Cush @RheumNow ( View Tweet )
1 year 8 months ago
MarketScan Claims & Medicaid study of incident AS, PsA, or RA (2010–2017) that Opioid use was highly prevalent in AS (36%), PsA (30%), & RA (44%) in the year prior to Dx & during the 1st Yr. Is this PCP or Rheumatologist mismanagement? https://t.co/YsCOLZUCfS https://t.co/b33uNg6Ucx
Dr. John Cush @RheumNow ( View Tweet )
1 year 8 months ago
Insurance claims data studied 7580 newly Dx RA (2018-2020) - 1998 tofacitinib vs 5582 adalimumab. After propensity matching, dyslipidemia was signif. higher w/ TOFA (HR 1.25), BUT no differences in MACE (HR 0.995) or all-cause mortality (HR, 1.4; NS) https://t.co/ZJ7uHWTycS https://t.co/A6tSm4RipS
Dr. John Cush @RheumNow ( View Tweet )
1 year 8 months ago
Legal (Not So) Merry-Go-Round of Alendronate Atypical Fractures
Dr. Gregory Curfman, MD writes on the chronological legal progress of a lawsuit stemming from rare instances of atypical femoral fractures associated with bisphosphonate (alendronate) use.
https://t.co/6Ipvw7tcKr https://t.co/VNrMg88AsH
Dr. John Cush @RheumNow ( View Tweet )
1 year 8 months ago
Antacids can Diminish Bone Density
Proton pump inhibitors (PPIs), a specific class of antacid drugs, are among the most widely used medications of all. They are frequently prescribed to many groups of patients, including those with rheumatism.
https://t.co/Ii8DlDgBx7 https://t.co/cWN7v7PiIf
Dr. John Cush @RheumNow ( View Tweet )
1 year 8 months ago
Retrospective 170 RA pts Rx w/ IFX, ADA, & CZP shows CZP levels didnt differ w/ low or HI RF; but high basel RF linked to lower IFX & ADA drug levels, W/O DAS28 differences, but more IFX/ADA D/C w/ Hi baseline RF levels (80% vs. 75% vs. 33% CZP, p=0.002) https://t.co/OVUcKAgJ5a https://t.co/kzWd8jHXs3
Dr. John Cush @RheumNow ( View Tweet )
1 year 8 months ago
Consensus Statements on Vitamin D
The “Controversies in Vitamin D” International Conference has published their proceedings on vitamin D metabolism, assessment, actions, and supplementation.
https://t.co/QGXbJdJpAC https://t.co/N1UkTi6u8C
Dr. John Cush @RheumNow ( View Tweet )
1 year 8 months ago
Small-molecule Drugs to Treat Systemic Lupus Erythematosus
A metanalysis of randomized controlled trials (RCTs) on treatments of systemic lupus erythematosus (SLE), confirm the efficacy of several targeted small-molecule drugs.
https://t.co/O3Y3KBngau https://t.co/wiB1EMtMFK
Dr. John Cush @RheumNow ( View Tweet )
1 year 8 months ago
Interferons and Lupus Subsets
In a new study, researchers from Johns Hopkins Medicine say they have uncovered insights as to the relationship between interferons and lupus, which affects up to 1.5 million Americans.
https://t.co/Eo8q3IGPb7 https://t.co/gVyHJwZFwc
Dr. John Cush @RheumNow ( View Tweet )
1 year 8 months ago
Risk Factors for Hydroxychloroquine Retinopathy
A long-term hydroxychloroquine users study found that 2.7% developed retinopathy, and identified risk factors as increasing age, female sex, chronic kidney disease stage 3+ and tamoxifen use.
https://t.co/iC7eh0XLzE https://t.co/gDaWi4kt1h
Dr. John Cush @RheumNow ( View Tweet )
1 year 8 months ago


